The Daily Toke

March 22, 2026

Sweeping changes to cannabis regulation are reshaping the political landscape across multiple states this March, with conflicting approaches exposing deep fractures in how America's cannabis renaissance is being managed. Pennsylvania's Senate committee voted 10-1 to amend its Cannabis Control Board bill, adding provisions to ban most hemp-derived THC products ahead of a federal policy shift taking effect in November—a move Senator Dan Laughlin frames as closing "loopholes that allowed intoxicating hemp products to flood the marketplace with little oversight." Meanwhile, Ohio's Republican lawmakers have essentially rewritten the cannabis law voters approved overwhelmingly in 2023, with Senate Bill 56 taking effect March 20 to restrict hemp products, ban THC beverages, criminalize public consumption, and eliminate legal protections for cannabis users—consequences that prompted activists to attempt a referendum, only to fall short of the 250,000 signatures needed by their March 19 deadline.

Virginia is charting a notably different course. Lawmakers approved legislation establishing a regulated retail market for adult-use cannabis five years after legalizing possession, with sales expected to launch in 2027 and a new Cannabis Control Authority issuing streamlined licensing guidelines alongside social equity programs for minority-owned cannabis businesses. 🚀 THIS IS COOL Virginia's approach includes strict product testing and labeling requirements designed to build consumer confidence in the legal market rather than restrict access. Louisiana has similarly introduced House Bill 373, which would create a temporary "adult-use cannabis pilot program" running from 2027 through 2030, though the plan faces criticism from entrepreneurs and consumer advocates who argue the structure reinforces a two-company duopoly and blocks competition for years—meaning existing license holders like Good Day Farm and Ilera Holistic Healthcare benefit while new market entry remains closed off.

Tennessee Democrats have filed the "Pot for Potholes Act," attempting to tie marijuana legalization revenue to infrastructure spending in a creative bid to reframe cannabis as a public works solution. 💰 MONEY MOVES The $28.4 billion hemp and cannabis market Comer is fighting to protect represents genuine economic activity—tax revenue, jobs, and consumer choice in states that have legalized—yet federal policy remains unchanged, creating a patchwork where Ohio can ban THC beverages while Pennsylvania prepares infrastructure to regulate them, and Virginia builds a legal supply chain precisely because voters demanded it. Pennsylvania's Laughlin, who is also sponsoring bipartisan legalization legislation, acknowledged the core tension: "Right now, there are too many gray areas in the law." Ohio's approach—eliminating legal protections for cannabis users, banning public consumption as a misdemeanor, and restricting where products can be sold—contradicts the democratic will of voters who approved legalization in 2023, with House Minority Leader Dani Isaacsohn stating plainly: "Ohioans deserve a government that honors their vote—not one that rewrites it."

The pattern emerging across these states reveals two competing visions. One treats cannabis as a legitimate product deserving regulatory clarity, consumer safety, and market access—what Virginia and Louisiana are attempting, albeit with varying equity frameworks. The other doubles down on restriction, treating the plant as a problem to be managed rather than a consumer choice to be regulated. 🤔 THINK ABOUT IT Alcohol kills approximately 95,000 Americans annually, and prescription opioids kill over 16,000 per year, yet neither faces the restrictions being imposed on cannabis, which has never caused an overdose death in recorded human history. The question becomes not whether cannabis will be normalized—that's already happening across the country—but whether regulation will actually serve consumers and communities, or simply shuffle market power among existing players while politicians insist they're protecting public health.

March 22, 2026

States are racing to tighten regulations on intoxicating hemp products as a federal policy shift looms later this year, creating a patchwork of new rules that ranges from outright bans to carefully calibrated retail restrictions. Ohio became the first state to fully implement these restrictions when Senate Bill 56 took effect on March 20, prohibiting the sale of intoxicating hemp and THC beverages in smoke shops, bars, and breweries. The law also caps THC potency in extracts at 70 percent and flower at 35 percent—dramatic reductions from the previous 90 percent threshold. A Franklin County judge rejected a last-minute challenge to block the restrictions, and Ohioans for Cannabis Choice failed to collect enough signatures to force a referendum before the Thursday deadline, effectively sealing the law's implementation.

Pennsylvania and South Carolina are charting notably different courses. In Pennsylvania, Sen. Dan Laughlin's Senate Bill 49 moved forward with a 10-1 committee vote on March 16 after amendments that would ban most hemp THC products, aligning state law with the pending federal definition change set for November. Laughlin framed the move as necessary because "the current system is fragmented" and regulators need "clear oversight" to keep "illegal and potentially harmful products off store shelves." South Carolina's Senate, however, narrowly rejected an outright ban last week and instead passed sweeping regulations on March 20 that keep some hemp products legal while heavily restricting them. The compromise allows low-dose THC gummies and 5-milligram drinks to remain available at general retailers, but limits 10-milligram drinks to liquor stores and bans on-premise consumption at bars and restaurants. 💰 MONEY MOVES The difference matters—an industry spokesperson warned that an Ohio-style ban would shut down approximately 6,000 businesses and eliminate thousands of jobs, while South Carolina's regulatory approach preserves the market but tightens control.

Rhode Island regulators are moving toward a middle ground. The state's Cannabis Control Commission recommended in its March 1 report that lawmakers codify a ban on THC drink sales at venues with liquor licenses, after over 100 bars and restaurants obtained licenses to sell intoxicating beverages between August 2024 and July 2025. The hospitality industry is pushing back hard—Farouk Rajab, CEO of the Rhode Island Hospitality Association, called the commission's stance a form of industry targeting and expressed skepticism that the decisions weren't predetermined. The regulatory confusion stems from the 2018 Farm Bill, which legalized hemp with a maximum 0.3 percent delta-9 THC dry weight, creating a legal gray area: while the hemp itself stays within federal limits, when processed into edibles and drinks, manufacturers can include substantially higher amounts per serving.

Behind these state-level decisions sits a significant federal policy shift. Congressional researchers updated their analysis of marijuana scheduling in mid-March, noting that while the Trump administration issued an executive order in December directing the Department of Justice to move cannabis from Schedule I to Schedule III, that rescheduling process has not materialized. The researchers emphasized that even if rescheduling occurred, it would not automatically bring state-legal marijuana or hemp industries into federal compliance without additional congressional action. This backdrop explains why states like Pennsylvania are moving proactively to align with expected federal hemp restrictions—they're effectively preempting the November federal deadline rather than waiting for clarity from Washington.

The regulatory debate reveals deeper tensions between public health concerns, economic interests, and government overreach. South Carolina Sen. Richard Cash argued that hemp products are "unknown, under-researched and dangerous," while supporters of regulation point to medicinal applications and the small businesses dependent on the market. 🤔 THINK ABOUT IT The states implementing these restrictions consistently cite child safety, yet alcohol—a substance that kills approximately 95,000 Americans annually and is the number-one drug-related killer of teenagers—remains fully legal and licensed for retail sale. Meanwhile, cannabis has never caused a recorded overdose death in human history. The regulatory patchwork across states suggests that neither prohibition nor laissez-faire oversight is winning the debate—instead, lawmakers are settling on what they hope is a middle path: keeping products available through tightly controlled channels with strict potency limits, age verification, and packaging requirements.

March 22, 2026

Largest scientific review in 45 years finds no evidence that medicinal cannabis effectively treats depression, anxiety, or PTSD — the three psychiatric conditions most commonly cited by patients seeking the drug — raising urgent questions about prescribing practices that have exploded across Australia and beyond. Researchers at the University of Sydney analyzed 54 randomized controlled trials spanning 1980 to 2025 in a landmark Lancet Psychiatry study published this month, examining cannabidiol (CBD), tetrahydrocannabinol (THC), and combined formulations across mental health and substance-use disorders. The findings are stark: no meaningful clinical benefit for anxiety, depression, PTSD, psychotic disorders, anorexia, or opioid use disorder — conditions that make up six of the top ten reasons cannabis is prescribed in Australia today.

💰 MONEY MOVES The gap between market expansion and clinical evidence is staggering. Around 700,000 Australians have used medicinal cannabis in the past year, and since 2022, sales have increased four-fold, yet the majority of products prescribed in Australia remain unregistered with the Therapeutic Goods Administration, meaning they've bypassed rigorous testing. Dr. Jack Wilson, the study's lead author, emphasized the clinical contradiction: "In the absence of evidence at this time, the routine use of medical cannabis products really should be rarely justified for the treatment of mental health disorders." He also flagged a darker possibility — that routine cannabis use could be doing more harm than good, increasing risks of psychotic symptoms and cannabis use disorder while delaying access to proven treatments.

There were narrow bright spots. The research found modest evidence that medicinal cannabis might help reduce cannabis use among people with cannabis use disorder itself — a paradoxical finding explained by the fact that CBD-THC combinations can reduce cravings, causing patients to use less of their usual product. Some limited, low-quality evidence emerged for autism, insomnia, and tics or Tourette's syndrome, though Wilson cautioned that these findings warrant careful interpretation. Meanwhile, CBD's stability as a medicine just improved significantly. 🚀 THIS IS COOL A new study from East China University of Science and Technology found that powder-based CBD formulations using cyclodextrin complexes retain over 90% of cannabidiol under standard conditions, compared to roughly 20% retention in traditional oil formulations exposed to light — a breakthrough that could extend shelf life and ensure consistent potency in future products, assuming they're actually tested and proven effective first.

The larger context matters. Cannabis has been listed as a Schedule I drug by the U.S. Drug Enforcement Administration for over 50 years, a classification that has made large-scale, high-quality clinical trials exceptionally difficult and expensive to fund. 🤔 THINK ABOUT IT When the FDA has approved specific cannabinoid drugs — Epidiolex for rare seizure disorders, Marinol and Cesamet for chemotherapy-induced nausea — those approvals came after rigorous testing. Yet the medicinal cannabis market has grown explosively without that same evidentiary standard, driven partly by patient desperation, partly by genuine regulatory gaps, and partly by commercial interest in a newly-legal sector. The irony is that cannabis does show genuine therapeutic promise for certain conditions — evidence supports its use for some forms of epilepsy, multiple sclerosis spasticity, and chronic pain — but mental health, where patients most often turn to it, isn't one of them.

What happens next matters more than the study itself. Wilson's team made clear that the absence of evidence isn't evidence of absence — more rigorous trials are needed — but in the absence of those trials, prescribing practices should shift dramatically. Some patients will continue using cannabis for mental health regardless, driven by personal experience or lack of alternatives. Others will discover their conditions might respond better to proven treatments. And the formulation science, now improving, will be ready to support whatever future clinical evidence emerges. The public's embrace of cannabis for mental health has far outpaced the science. This study, the largest systematic review ever conducted on the question, is a signal to catch up.

March 22, 2026

Texas hemp retailers are bracing for what could be the most disruptive regulatory shift in the state's emerging cannabis industry. Starting March 31, new rules from the Texas Department of State Health Services will fundamentally change how the state measures THC legality by counting THCA—the non-intoxicating precursor compound that converts to delta-9 THC when heated—as part of "Total THC." The shift will effectively ban smokable hemp products, which currently represent 50 to 70 percent of sales for many retailers across the state. 💰 MONEY MOVES Combined with a licensing fee increase from $155 to $5,000 annually for retailers and $258 to $10,000 for manufacturers—a hike of roughly 3,200 percent—the changes threaten the viability of hundreds of small businesses that have built their operations around THCA flower and concentrates over the past several years.

The four-week implementation window has drawn criticism from industry experts and business owners alike. Allen Kirk, managing partner at Full Spectrum in San Angelo, described the timeline as unrealistic: if his store loses 35 to 50 percent of its inventory to the new rules while facing a $4,845 increase in annual licensing fees, he said the math becomes difficult to manage. "Imagine being a business and finding out that not only are your registration fees going up significantly, but also 50 percent—maybe even 70 percent—of the products that you sell now have to be taken off the shelves in a matter of weeks," said Heather Fazio, director of the Texas Cannabis Policy Center. Some retailers, including those specializing exclusively in flower products, have already begun closing their doors in anticipation of the rules taking effect. Jacob Warner, co-owner of Alamo Bud Co. in San Antonio, told reporters that 70 percent of his sales are smokable products, and competitors have already informed him they plan to shut down entirely after March 31.

The regulatory shift carries real consequences for a specific population: veterans and patients using THCA products for PTSD, chronic pain, and anxiety. Smokable products deliver faster relief than edibles or oils—Kirk noted that inhaled products provide "instant relief, whereas gummies or oils take 45 minutes to an hour and a half to work." When legal access narrows or closes, those customers don't simply disappear from the market. Kirk raised a legitimate concern that has played out in other prohibition contexts: "Customers are going to go back to the street. They're going to buy sketchy products from sketchy individuals." 🤔 THINK ABOUT IT Unregulated street products carry actual safety risks—no third-party testing, no quality assurance, no accountability. Regulated markets at least provide consumer protections that informal markets cannot.

The rules also mandate stricter age verification, more rigorous product testing, and enhanced recordkeeping—measures that supporters, including Gov. Greg Abbott's office, say are designed to improve consumer safety and industry oversight. Abbott issued Executive Order GA-56 in September 2025, directing DSHS to tighten regulations after the Texas legislature spent much of 2025 debating whether to ban THC products entirely or regulate them instead. The governor vetoed an outright ban in favor of this regulatory approach, yet the compressed timeline and severity of the changes suggest that regulation and prohibition may be functionally equivalent for many existing businesses.

💰 MONEY MOVES The licensing fee increases are particularly steep when compared to other regulated industries in Texas. Kirk observed that the new hemp license fees exceed what alcohol retailers pay, a notable irony given that alcohol causes approximately 95,000 deaths annually in the United States, while cannabis has zero recorded overdose deaths in human history. The financial barrier alone may force smaller operators out of the market, consolidating the industry toward larger players with greater capital reserves. Jacqueline Walji, owner of Mellow Monkey in San Antonio, said other shop owners have already told her they're closing. "I've even noticed when I'm driving around that I've already seen some of them shut down," she said. The March 31 deadline marks a hard stop—products that don't comply must be removed from shelves immediately, with no grace period for inventory adjustment or business restructuring.

The Texas situation reflects a broader national pattern: states are regulating hemp-derived intoxicating products more aggressively even as cannabis normalization continues elsewhere. The regulatory framework targets THCA specifically, yet business owners and policy advocates question whether the timing and severity of these rules actually serve the stated goal of consumer protection or instead function as a de facto ban through compliance costs and timelines that small businesses cannot meet. What remains to be seen is whether Texas hemp retailers can adapt their business models to focus on non-smokable products like gummies, creams, and topicals that meet the new THC limits—or whether many will simply exit the market by April 1st, 2026.